Patent intelligence · US
US 12097261
CDK2 degraders and uses thereof
CDK2 degraders and uses thereof
Patent details — US 12097261
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 24, 2024
- Expiration
- Sep 19, 2044
- Applicant
- Kymera Therapeutics, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K47/55, A61P, A61P35/00
Quick answer
US 12097261 (CDK2 degraders and uses thereof) is held by Kymera Therapeutics, Inc.. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kymera Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K47/55, A61P, A61P35/00
More from Kymera Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12258341
IRAK degraders and uses thereof
granted -
US 12187744
IRAK4 degraders and synthesis thereof
granted -
US 12171768
IRAK4 degraders and uses thereof
granted -
US 12168057
IRAK degraders and uses thereof
granted -
US 12150995
IRAK degraders and uses thereof
granted -
US 12091411
IRAK degraders and uses thereof
granted -
US 12077555
STAT degraders and uses thereof
granted
Frequently asked questions
What is US patent 12097261?
US 12097261 (CDK2 degraders and uses thereof) is held by Kymera Therapeutics, Inc.. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12097261?
Kymera Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 12097261 expire?
Our index shows an expiration date of Sep 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.